Project Grant R42DK138551
Award Date 9/9/25
Completion Date 7/31/28
Dollars Obligated $975K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
- This federal Project Grant award of $350,000 was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The objective is to validate the use of AVGN7 (rAAV6:SMAD7), a gene therapeutic, for treating obesity and type 2 diabetes mellitus (T2DM). The key products or services to be delivered include: (1) Demonstrating that AVGN7 can restore lean body mass and insulin...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $773,112 Project Grant to Rockefeller University on September 5, 2025 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research to investigate the mechanisms of transcriptional control in adipocyte formation and function through nuclear receptor coactivators. The research aims to provide a better understanding of dysregulation in energy storage...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $719,250 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Biotherapeutics, Inc., a clinical-stage biotech company in Virginia. The grant supports the development of novel, oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes (T2D). The specific aims are to: 1) Evaluate the therapeutic efficacy of the lead drug candidate...
- This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to test the effectiveness of tirzepatide for treating familial partial lipodystrophy (FPLD). FPLD is a rare metabolic disorder characterized by loss of fat tissue in the limbs and trunk, leading to metabolic and endocrine complications. The $793,098 award to the Regents of the...
- This Project Grant award of $307,508 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to develop a novel bioengineered brown adipocyte (fat cell) transplant as a potential new therapy for treating obesity and associated metabolic disorders. The award will fund research by United Biotherapeutics LLC to further develop a safer and more efficient adeno-associated...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a component of the National Institutes of Health, awarded a $350,000 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Microvascular Tissues, Inc. The grant supports the evaluation of a microvascular tissue graft treatment in rat models of diabetic peripheral neuropathy. The project aims to assess the ability of this novel microvascular tissue graft to improve...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $752,158 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Rerx Therapeutics, Inc. to develop a small molecule therapeutic to address obesity and associated metabolic disorders. The goal is to investigate the efficacy and safety of RERX-001, an orally bioavailable small molecule that targets lipid homeostasis and energy metabolism, in diet-induced...
- This $1,021,719.00 federal Project Grant award was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant recipient, Emmyon, Inc., is developing a novel small molecule therapeutic (EMMY1-25) that has demonstrated the ability to promote weight loss without muscle loss and protect against dysfunction of pancreatic beta cells in mouse models of obesity and type 2...
- This federal Project Grant award of $464,985, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), supports research on extracellular vesicles released by adipocytes (fat cells) and their potential role in cardiometabolic disease. The research, conducted by The Washington University, aims to investigate how these adipocyte-derived extracellular vesicles, including...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $621,794 Project Grant to Islex Therapeutics, LLC on August 1, 2025. The grant supports the preclinical development of a therapeutic antibody for treating type 1 diabetes (T1D), a chronic autoimmune disease affecting approximately 1.5 million Americans. The objective is to establish proof-of-principle for a humanized...